217 related articles for article (PubMed ID: 6223674)
1. High-dose cytosine arabinoside therapy for refractory leukemia.
Herzig RH; Wolff SN; Lazarus HM; Phillips GL; Karanes C; Herzig GP
Blood; 1983 Aug; 62(2):361-9. PubMed ID: 6223674
[TBL] [Abstract][Full Text] [Related]
2. Phase I-II clinical and pharmacologic studies of high-dose cytosine arabinoside in refractory leukemia.
Kantarjian HM; Estey EH; Plunkett W; Keating MJ; Walters RS; Iacoboni S; McCredie KB; Freireich EJ
Am J Med; 1986 Sep; 81(3):387-94. PubMed ID: 3463209
[TBL] [Abstract][Full Text] [Related]
3. High-dose cytosine arabinoside therapy with and without anthracycline antibiotics for remission reinduction of acute nonlymphoblastic leukemia.
Herzig RH; Lazarus HM; Wolff SN; Phillips GL; Herzig GP
J Clin Oncol; 1985 Jul; 3(7):992-7. PubMed ID: 3894588
[TBL] [Abstract][Full Text] [Related]
4. [Value of high-dose cytosine-arabinoside in the treatment of resistant acute leukemia].
Witz F; Olive D; Lederlin P; Bordigoni P; Troussard X; Grosbois B; Schaison G; Cornu G
Presse Med; 1987 Feb; 16(4):159-62. PubMed ID: 2950446
[TBL] [Abstract][Full Text] [Related]
5. High-dose cytosine arabinoside, daunomycin and 6-thioguanine in relapsed or refractory acute nonlymphocytic leukemia.
Garewal H; Durie BG; Greenberg B
Oncology; 1987; 44(6):333-5. PubMed ID: 3684173
[TBL] [Abstract][Full Text] [Related]
6. Fludarabine and cytarabine as a sequential infusion regimen for treatment of adults with recurrent, refractory or poor prognosis acute leukemia.
Vidarsson B; Abonour R; Williams EC; Woodson RD; Turman NJ; Kim K; Mosher DF; Wiersma SR; Longo WL
Leuk Lymphoma; 2001 Apr; 41(3-4):321-31. PubMed ID: 11378544
[TBL] [Abstract][Full Text] [Related]
7. Central nervous system toxicity of high-dose systemic cytosine arabinoside.
Lazarus HM; Herzig RH; Herzig GP; Phillips GL; Roessmann U; Fishman DJ
Cancer; 1981 Dec; 48(12):2577-82. PubMed ID: 7306918
[TBL] [Abstract][Full Text] [Related]
8. Treatment of refractory leukemia with high-dose cytosine arabinoside.
Klener P; Háber J
Neoplasma; 1985; 32(1):113-7. PubMed ID: 3856754
[TBL] [Abstract][Full Text] [Related]
9. [High-dose cytosine arabinoside treatment of leukemia with special reference to the optimal number of doses].
Sampi K; Maseki N; Kumai R; Kaneko Y; Sakurai M; Hattori M
Gan To Kagaku Ryoho; 1989 Aug; 16(8 Pt 1):2595-8. PubMed ID: 2774589
[TBL] [Abstract][Full Text] [Related]
10. Phase I trial with escalating doses of idarubicin and multidrug resistance reversal by short-course cyclosporin A, sequential high-dose cytosine arabinoside, and granulocyte colony-stimulating factor for adult patients with refractory acute leukemia.
Bassan R; Lerede T; Borleri G; Chiodini B; Rossi A; Buelli M; Rambaldi A; Viero P; Barbui T
Haematologica; 2002 Mar; 87(3):257-63. PubMed ID: 11869937
[TBL] [Abstract][Full Text] [Related]
11. High-dose cytosine arabinoside in combination with mitoxantrone for the treatment of refractory acute myeloid and lymphoblastic leukemia.
Hiddemann W; Kreutzmann H; Straif K; Ludwig WD; Mertelsmann R; Planker M; Donhuijsen-Ant R; Lengfelder E; Arlin Z; Büchner T
Semin Oncol; 1987 Jun; 14(2 Suppl 1):73-7. PubMed ID: 3473685
[TBL] [Abstract][Full Text] [Related]
12. High-dose cytosine arabinoside and mitoxantrone in previously-treated acute leukemia patients.
Lejeune C; Tubiana N; Gastaut JA; Maraninchi D; Richard B; Launay MC; Sainty D; Sebahoun G; Carcassonne Y
Eur J Haematol; 1990 Apr; 44(4):240-3. PubMed ID: 2344886
[TBL] [Abstract][Full Text] [Related]
13. High-dose cytosine arabinoside and mitoxantrone: a highly effective regimen in refractory acute myeloid leukemia.
Hiddemann W; Kreutzmann H; Straif K; Ludwig WD; Mertelsmann R; Donhuijsen-Ant R; Lengfelder E; Arlin Z; Büchner T
Blood; 1987 Mar; 69(3):744-9. PubMed ID: 3469002
[TBL] [Abstract][Full Text] [Related]
14. High-dose cytosine arabinoside and etoposide: an effective regimen without anthracyclines for refractory childhood acute non-lymphocytic leukemia.
Whitlock JA; Wells RJ; Hord JD; Janco RL; Greer JP; Gay JC; Edwards JR; McCurley TL; Lukens JN
Leukemia; 1997 Feb; 11(2):185-9. PubMed ID: 9009078
[TBL] [Abstract][Full Text] [Related]
15. High-dose cytosine arabinoside for acute nonlymphocytic leukemia.
Cantin G; Brennan JK
Am J Hematol; 1984 Jan; 16(1):59-66. PubMed ID: 6695910
[TBL] [Abstract][Full Text] [Related]
16. Treatment of poor risk acute leukemia with sequential high-dose ARA-C and asparaginase.
Capizzi RL; Poole M; Cooper MR; Richards F; Stuart JJ; Jackson DV; White DR; Spurr CL; Hopkins JO; Muss HB
Blood; 1984 Mar; 63(3):694-700. PubMed ID: 6696996
[TBL] [Abstract][Full Text] [Related]
17. Central nervous system toxicity of high-dose cytosine arabinoside.
Grossman L; Baker MA; Sutton DM; Deck JH
Med Pediatr Oncol; 1983; 11(4):246-50. PubMed ID: 6888324
[TBL] [Abstract][Full Text] [Related]
18. Remission maintenance for acute nonlymphocytic leukemia: cytosine arabinoside plus 6-thioguanine versus a sequence of drug regimens.
Presant CA; Berger NA; Klahr C; Phillips GL
Cancer; 1980 Jul; 46(1):22-8. PubMed ID: 6930320
[TBL] [Abstract][Full Text] [Related]
19. A randomized comparison of postremission therapy in acute myelogenous leukemia: a Southeastern Cancer Study Group trial.
Vogler WR; Winton EF; Gordon DS; Raney MR; Go B; Meyer L
Blood; 1984 May; 63(5):1039-45. PubMed ID: 6201211
[TBL] [Abstract][Full Text] [Related]
20. Phase I study of aziridinylbenzoquinone (AZQ, NSC 182986) in children with cancer.
Tan CT; Hancock CH; Mondora A; Hoffman NW
Cancer Res; 1984 Feb; 44(2):831-5. PubMed ID: 6692381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]